The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | The promise of CD123-targeted therapy in BPDCN
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights CD123-targeting agents being explored for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including tagraxofusp and pivekimab sunirine. Dr Pemmaraju also comments on the potential of CD123-targeted CAR-T therapy and the importance of further investigating this approach. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
